06:51 AM EST, 03/07/2024 (MT Newswires) -- GSK (GSK) said Thursday that it had received positive results from an interim analysis of a late-stage study of its potential multiple myeloma treatment Blenrep in combination with pomalidomide plus dexamethasone compared with bortezomib plus dexamethasone.

The company said the trial, involving 302 patients, met its primary endpoint of progression-free survival at a pre-specified interim analysis in relapsed or refractory multiple myeloma patients.

The Blenrep, also known as belantamab mafodotin, combination "significantly extended the time to disease progression or death versus the standard of care combination," the company said.

Multiple myeloma is a blood cancer considered treatable but not curable.

GSK shares were up more nearly 3% in recent Thursday premarket activity.

Price: 43.76, Change: +1.14, Percent Change: +2.67